Cited 8 times in
Selection of a mobilization regimen for multiple myeloma based on the response to induction therapy: granulocyte-colony stimulating factor (G-CSF) alone versus high-dose cyclophosphamide plus G-CSF.
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 김수정 | - |
dc.contributor.author | 김진석 | - |
dc.contributor.author | 장지은 | - |
dc.contributor.author | 정준원 | - |
dc.contributor.author | 조현수 | - |
dc.contributor.author | 조현수 | - |
dc.date.accessioned | 2017-02-27T07:25:30Z | - |
dc.date.available | 2017-02-27T07:25:30Z | - |
dc.date.issued | 2016 | - |
dc.identifier.issn | 1042-8194 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/146877 | - |
dc.description.abstract | To evaluate the feasibility of selecting amobilizationregimenbasedon theresponsetoinductiontherapy, we retrospectively analyzed 179multiplemyelomapatients who underwent stem cellmobilization. In comparison with patients who achieved at least a very good partialresponse(VGPR) toinductiontherapyand receivedgranulocyte-colonystimulatingfactor(G-CSF)aloneand patients who did not achieve a VGPR and receivedcyclophosphamide(CY) + G-CSF, treatment-related toxicity was greater and neutrophil engraftment was slower in the CY than theG-CSFgroup. The rate of requisitemobilization(≥ 2.0 × 10(6)/kg) was similar in both groups. Overall and progression-free survival was not different between patients in theG-CSFgroup and patients who achieved at least VGPR and received CY + G-CSF. In conclusion,response-adaptedselectionof amobilizationregimenis appropriate.G-CSFaloneshould be the preferred treatment for patients who achieved at least a VGPR toinductiontherapy. | - |
dc.description.statementOfResponsibility | restriction | - |
dc.language | English | - |
dc.publisher | Informa Healthcare | - |
dc.relation.isPartOf | LEUKEMIA & LYMPHOMA | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.rights.uri | https://creativecommons.org/licenses/by-nc-nd/2.0/kr/ | - |
dc.subject.MESH | Aged | - |
dc.subject.MESH | Antineoplastic Combined Chemotherapy Protocols/therapeutic use* | - |
dc.subject.MESH | Cyclophosphamide/administration & dosage | - |
dc.subject.MESH | Female | - |
dc.subject.MESH | Granulocyte Colony-Stimulating Factor/administration & dosage | - |
dc.subject.MESH | Granulocyte-Macrophage Colony-Stimulating Factor/administration & dosage | - |
dc.subject.MESH | Hematopoietic Stem Cell Mobilization*/methods | - |
dc.subject.MESH | Hematopoietic Stem Cell Transplantation* | - |
dc.subject.MESH | Humans | - |
dc.subject.MESH | Male | - |
dc.subject.MESH | Middle Aged | - |
dc.subject.MESH | Multiple Myeloma/diagnosis | - |
dc.subject.MESH | Multiple Myeloma/mortality | - |
dc.subject.MESH | Multiple Myeloma/therapy* | - |
dc.subject.MESH | Remission Induction | - |
dc.subject.MESH | Transplantation Conditioning*/adverse effects | - |
dc.subject.MESH | Transplantation Conditioning*/methods | - |
dc.subject.MESH | Transplantation, Autologous | - |
dc.subject.MESH | Treatment Outcome | - |
dc.title | Selection of a mobilization regimen for multiple myeloma based on the response to induction therapy: granulocyte-colony stimulating factor (G-CSF) alone versus high-dose cyclophosphamide plus G-CSF. | - |
dc.type | Article | - |
dc.publisher.location | England | - |
dc.contributor.college | College of Medicine | - |
dc.contributor.department | Dept. of Internal Medicine | - |
dc.contributor.googleauthor | Ji Eun Jang | - |
dc.contributor.googleauthor | June-Won Cheong | - |
dc.contributor.googleauthor | Soo-Jeong Kim | - |
dc.contributor.googleauthor | Hyunsoo Cho | - |
dc.contributor.googleauthor | Cheolwon Suh | - |
dc.contributor.googleauthor | Hyewon Lee | - |
dc.contributor.googleauthor | Hyeon-Seok Eom | - |
dc.contributor.googleauthor | Ho-Young Yhim | - |
dc.contributor.googleauthor | Won-Sik Lee | - |
dc.contributor.googleauthor | Chang-Ki Min | - |
dc.contributor.googleauthor | Jae Hoon Lee | - |
dc.contributor.googleauthor | Joon Seong Park | - |
dc.contributor.googleauthor | Jin Seok Kim | - |
dc.identifier.doi | 10.3109/10428194.2015.1102240 | - |
dc.contributor.localId | A00633 | - |
dc.contributor.localId | A01017 | - |
dc.contributor.localId | A03477 | - |
dc.contributor.localId | A03729 | - |
dc.relation.journalcode | J02165 | - |
dc.identifier.eissn | 1029-2403 | - |
dc.identifier.pmid | 26428939 | - |
dc.identifier.url | http://www.tandfonline.com/doi/abs/10.3109/10428194.2015.1102240 | - |
dc.subject.keyword | Cyclophosphamide | - |
dc.subject.keyword | granulocyte-colony stimulating factor | - |
dc.subject.keyword | multiple myeloma | - |
dc.subject.keyword | stem cell mobilization | - |
dc.contributor.alternativeName | Kim, Soo Jeong | - |
dc.contributor.alternativeName | Kim, Jin Seok | - |
dc.contributor.alternativeName | Jang, Ji Eun | - |
dc.contributor.alternativeName | Cheong, June Won | - |
dc.contributor.alternativeName | Cho, Hyun Soo | - |
dc.contributor.affiliatedAuthor | Kim, Soo Jeong | - |
dc.contributor.affiliatedAuthor | Kim, Jin Seok | - |
dc.contributor.affiliatedAuthor | Jang, Ji Eun | - |
dc.contributor.affiliatedAuthor | Cheong, June-Won | - |
dc.citation.volume | 57 | - |
dc.citation.number | 6 | - |
dc.citation.startPage | 1389 | - |
dc.citation.endPage | 1397 | - |
dc.identifier.bibliographicCitation | LEUKEMIA & LYMPHOMA, Vol.57(6) : 1389-1397, 2016 | - |
dc.date.modified | 2017-02-24 | - |
dc.identifier.rimsid | 46444 | - |
dc.type.rims | ART | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.